The Biology of 3β-HSD: How the Diagnosis is Made

Understanding the biology of 3β-HSD deficiency requires looking at a specialized biochemical pathway. In the adrenal glands and gonads (testes and ovaries), the body is missing a critical enzyme needed to move hormone production forward ^[1][2]. This biological “block” explains why patients have low levels of some life-sustaining hormones and high levels of others.

The Delta-5 to Delta-4 Block

In a typical body, the adrenal glands take a starting material (cholesterol) and transform it through several steps into cortisol, aldosterone, and sex steroids. One of the earliest and most vital steps requires an enzyme called 3β-hydroxysteroid dehydrogenase type 2 (encoded by the HSD3B2 gene) ^[3][1].

Biochemically, hormones are grouped into families. The Δ5 (Delta-5) steroids are “early-stage” precursor hormones, while the Δ4 (Delta-4) steroids are “mature” hormones.

• The Problem: In 3β-HSD deficiency, the conversion of Δ5 steroids into Δ4 steroids is impaired ^[3].
• The Result: The precursor Δ5 hormones (like 17-hydroxypregnenolone and DHEA) pile up in massive amounts ^[4][5].
• The Deficiency: Because the pathway is blocked, the body cannot make enough of the mature hormones it needs to survive, specifically cortisol (for energy and stress response) and aldosterone (for salt balance) ^[1][2].

Why the Newborn Screen Can Be Confusing

Almost every baby is screened for CAH shortly after birth. However, these screens were designed specifically to find the most common type (21-hydroxylase deficiency) by looking for a marker called 17-OHP ^[6].

For 3β-HSD deficiency, the standard newborn screen can be misleading for two reasons:

1. The False Positive: A patient’s 17-OHP may be high, but not for the reason the screen assumes. A second version of the enzyme (type 1), located in the skin and placenta, can convert some of the “backlogged” hormones into 17-OHP ^[7][8]. This can lead doctors to wrongly suspect the common form of CAH ^[9].
2. The Missed Case: Sometimes, the 17-OHP level isn’t high enough to trigger the alarm, even though the patient is in danger of a salt-wasting crisis ^[10][11].

Because of this, a “passed” newborn screen does not always mean a child is clear of 3β-HSD, especially if they are showing symptoms like poor feeding or weight loss ^[10].

How Doctors Confirm the Diagnosis

To get a clear picture, doctors must look past the standard screen and use a sophisticated test called LC-MS/MS (Liquid Chromatography-Mass Spectrometry) alongside ACTH stimulation tests ^[5]. This evaluates the whole clinical and biochemical picture.

Key Biomarkers

• 17-hydroxypregnenolone: This is the primary precursor hormone. In 3β-HSD deficiency, this level is extremely high ^[4][5].
• The Ratio: Doctors look at the 17-hydroxypregnenolone-to-cortisol ratio. A very high ratio strongly supports a 3β-HSD deficiency diagnosis ^[4][5].
• 21-deoxycortisol: This marker is used to tell the types apart. It is highly elevated in the common form of CAH but is typically much lower in 3β-HSD deficiency ^[6].

Genetic Confirmation

The diagnosis is supported by genetic testing of the HSD3B2 gene ^[11]. This test identifies the specific mutations involved. However, genetic testing is complex: it may reveal a “Variant of Uncertain Significance” (VUS) or fail to find both mutations. Furthermore, emergency treatment with hydrocortisone must never be delayed while waiting for genetic or advanced lab results if a patient is in crisis.

Differentiation Summary

By interpreting the entire clinical, biochemical, and genetic picture, your care team can confirm the location of the biochemical block and tailor a treatment plan to precisely replace what the body is unable to make ^[12].